The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere.
The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
• This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments: • Statins and Fixed-Dose Combinations • Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates • PCSK9 Inhibitors • Novel Cholesterol-Lowering Drugs
• This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment: • Crestor • Lipitor • Livalo • Lescol/Lescol XL • Zocor • Vytorin • Caduet • Others
• This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment: • Zetia • Welchol • Tricor • Others
• This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment: • Praluent • Repatha • RN316 • Others
• This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment: • Juxtapid • Kynamro • MK-0859 • Others
• This report provides individual revenue forecasts to 2027 for these regional and national markets: • North America: the US, Canada, Mexico • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America • Europe: Germany, France, the UK, Spain, Italy, Rest of Europe • Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC • RoW: Middle East, Africa, Other Countries
• Our study provides SWOT and Porter’s Five Forces analysis that influence the global cholesterol-lowering drugs market
• Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market: • AstraZeneca • Merck & Co • Pfizer • Kowa Company • Daiichi Sankyo • AbbVie • Novartis • Sanofi • Amgen • Bristol-Myers Squibb (BMS)
Visiongain’s study is intended for anyone requiring commercial analyses for the global cholesterol-lowering drugs market. You find data, trends and predictions.
Buy our report today Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Cholesterol-Lowering Drugs Market Overview 1.2 Research Methodology 1.2.1 Primary Research 1.2.2 Secondary Research 1.2.3 Market Evaluation & Forecasting Methodology 1.3 Global Cholesterol-Lowering Drugs Market Segmentation 1.4 Why You Should Read This Report 1.5 How this report delivers? 1.6 Key Questions Answered by This Analytical Report 1.7 Frequently Asked Questions (FAQ) 1.8 Who is This Report For? 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Cholesterol-Lowering Drugs 2.1 The Pharmaceutical Industry: A Brief Overview 2.2 Cholesterol: An Essential Lipid 2.3 The Functions of Cholesterol 2.4 Metabolism and Circulation of Cholesterol 2.5 The Role of Cholesterol in Heart Disease 2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy 2.6.1 The IMPROVE-IT Study 2.7 The Role of Cholesterol in Heart Disease: The Controversy 2.8 Raising HDL Cholesterol: A Worthwhile Aim? 2.9 Causes of Hypercholesterolaemia 2.9.1 Atherosclerosis 2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia 2.9.3 Familial Hypercholesterolaemia 2.10 Treatment of Hypercholesterolaemia 2.10.1 UK Treatment Guidelines for Hypercholesterolaemia 2.10.2 US Treatment Guidelines for Hypercholesterolaemia 2.10.3 Lifestyle Changes 2.10.4 Drugs to Lower Cholesterol 2.10.5 Other Therapeutic Approaches 2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment 2.10.5.2 LDL Apheresis: Directly Removing Cholesterol 2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
3. Global Cholesterol-Lowering Drugs Market Forecast 2017 - 2027 3.1 Global Cholesterol-Lowering Drugs Market by Type, 2017-2027 3.2 Cholesterol-Lowering Drugs Market: Statins and Fixed Dose Combination, 2017-2027 3.3 Cholesterol-Lowering Drugs Market: Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, 2017-2027 3.4 Cholesterol-Lowering Drugs Market: PCSK9 Inhibitors, 2017-2027 3.5 Cholesterol-Lowering Drugs Market: Novel Drugs, 2017-2027
4. Global Cholesterol-Lowering Drugs Market Segments, by Type: Market Forecast 2017 - 2027 4.1 Overview 4.2 Statins and Fixed-Dose Combinations Market Forecast 2017 - 2027 4.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Market Forecast 2017 - 2027 4.4 PCSK9 Inhibitors Market Forecast 2017 - 2027 4.5 Novel Cholesterol-Lowering Drugs Market Forecast 2017 – 2027
12. Conclusions 12.1 Leading Regional Markets: 2017-2027 12.2 Current Leading Segments: 2017-2027 12.3 World Cholesterol-Lowering Drugs Market: Market Driving Factors
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain report evaluation form
List of Tables Table 3.1. Global Cholesterol-Lowering Drugs Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($m, AGR%, CAGR%) 2017-2027 Table 4.2. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027 Table 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 4.5. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027 Table 4.6. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 4.7. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027 Table 4.8. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 4.9. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027 Table 5.1. Global Statins and Fixed-Dose Combinations Market by Product($m, AGR%, CAGR%) 2017-2027 Table 5.2. Global Crestor Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.3. Global Lipitor Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.4. Global Livalo Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.5. Global Lescol /Lescol XL Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.6. Global Zocor Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.7. Global Vytorin Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.8. Global Caduet Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 5.9. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m, AGR%, CAGR%) 2017-2027 Table 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($m, AGR%, CAGR%) 2017-2027 Table 6.2. Global Zetia Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 6.3. Global Welchol Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 6.4. Global Tricor Market Forecast($m, AGR%, CAGR%) 2017-2027 Table 6.5. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m, AGR%, CAGR%) 2017-2027 Table 7.1. Global PCSK9 Inhibitors Market by Product ($m, AGR%, CAGR%) 2017-2027 Table 7.2. Global Praluent Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 7.3. Global Repatha Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 7.4. Global RN316 Market Forecast ($m, AGR%, CAGR%) 2017-2027 Table 7.5. Global Others Market of the PCSK9 Inhibitors Segment ($m, AGR%, CAGR%) 2017-2027 Table 8.1. Global Novel Cholesterol-Lowering Drugs by Product ($m, AGR%, CAGR%) 2017-2027 Table 8.2. Global Juxtapid Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 8.3. Global Kynamro Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 8.4. Global MK-089 Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 8.5. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m, AGR%, CAGR%) 2017-2027 Table 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($m, AGR%, CAGR%) 2017-2027 Table 9.2. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027 Table 9.3. USA Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.4. Canada Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.5. Mexico Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.6. South America Cholesterol-Lowering Drugs Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027 Table 9.7. Brazil Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.8. Argentina Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.9. Paraguay Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.10. Bolivia Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.11. Rest of South America Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.12. European Cholesterol-Lowering Drugs Market Forecast by Country ($m, AGR%, CAGR%) 2017-2027 Table 9.13. France Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.14. Germany Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.15. UK Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.16. Spain Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.17. Italy Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.18. Rest of European Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.19. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027 Table 9.20. China Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.21. Japan Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.22. India Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.23. Australia Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.24. Thailand Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.25. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.26. Rest of World Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027 Table 9.27. Middle East Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.28. Africa Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 9.29. Other Countries Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027 Table 11.1. AstraZeneca Plc: Company Overview Table 11.2.. AstraZeneca Plc: Product Portfolio Table 11.3. AstraZeneca Plc: Recent Developments Table 11.4. Merck & Co. Inc.: Company Overview Table 11.5. Merck & Co. Inc.: Product Portfolio Table 11.6. Merck & Co. Inc.: Recent Developments Table 11.7. Pfizer Inc.: Company Overview Table 11.8. Pfizer Inc.: Product Portfolio Table 11.9. Pfizer Inc.: Recent Developments Table 11.10. Kowa Company, Ltd.: Company Overview Table 11.11. Kowa Company, Ltd.: Product Portfolio Table 11.12. Kowa Company, Ltd.: Recent Developments Table 11.13. Daiichi Sankyo Co., Ltd.: Company Overview Table 11.14. AbbVie Inc.: Company Overview Table 11.15. AbbVie Inc.: Product Portfolio Table 11.16. Novartis AG: Company Overview Table 11.17. Novartis AG: Product Portfolio Table 11.18. Novartis AG: Recent Developments Table 11.19. Sanofi S.A.: Company Overview Table 11.20. Sanofi S.A.: Product Portfolio Table 11.21. Sanofi S.A: Recent Developments Table 11.22. Amgen Inc.: Company Overview Table 11.23. Amgen Inc.: Product Portfolio Table 11.24. Amgen Inc.: Recent Developments Table 11.25. Bristol-Myers Squibb: Company Overview Table 11.26. Bristol-Myers Squibb : Product Portfolio
List of Figures Figure 1.1. Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015 Figure 2.1. Chemical Structure of Cholesterol, 2017 Figure 3.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($million) 2017-2027 Figure 3.2. Cholesterol-Lowering Drugs Market, by Statins and Fixed-Dose Combination, ($million) 2017-2027 Figure 3.3. Cholesterol-Lowering Drugs Market, by Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, ($million) 2017-2027 Figure 3.4. Cholesterol-Lowering Drugs Market, by PCSK9 Inhibitors, ($million)2017-2027 Figure 3.5. Cholesterol-Lowering Drugs Market, by Novel Cholesterol-Lowering Drugs, ($million) 2017-2027 Figure 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type, Market Share (%), 2016 Figure 4.2. Global Cholesterol-Lowering Drugs Market Segments, by Type, Forecast ($million) 2017-2027 Figure 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027 Figure 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027 Figure 4.5. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027 Figure 4.6. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027 Figure 5.1. Global Statins and Fixed-Dose Combinations Market by Product ($million) 2017-2027 Figure 5.2. Global Statins and Fixed-Dose Combinations Market Share of Products (%), 2016 Figure 5.3. Global Crestor Market Forecast ($m) 2017-2027 Figure 5.4. Global Lipitor Market Forecast ($m) 2017-2027 Figure 5.5. Global Livalo Market Forecast ($m) 2017-2027 Figure 5.6. Global Lescol /Lescol XL Market Forecast ($m) 2017-2027 Figure 5.7. Global Zocor Market Forecast ($m) 2017-2027 Figure 5.8. Global Vytorin Market Forecast ($m) 2017-2027 Figure 5.9. Global Caduet Market Forecast ($m) 2017-2027 Figure 5.10. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m) 2017-2027 Figure 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($million) 2017-2027 Figure 6.2. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market Share of Products (%), 2016 Figure 6.3. Global Zetia Market Forecast ($m) 2017-2027 Figure 6.4. Global Welchol Market Forecast ($m) 2017-2027 Figure 6.5. Global Tricor Market Forecast ($m) 2017-2027 Figure 6.6. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m) 2017-2027 Figure 7.1. Global PCSK9 Inhibitors Market Share of Products (%), 2016 Figure 7.2. Global PCSK9 Inhibitors Market by Product ($million) 2017-2027 Figure 7.3. Global Praluent Market Forecast, ($m) 2017-2027 Figure 7.4. Global Repatha Market Forecast, ($m) 2017-2027 Figure 7.5. Global RN316 Market Forecast, ($m) 2017-2027 Figure 7.6. Global Others Market of the PCSK9 Inhibitors Segment, ($m) 2017-2027 Figure 8.1. Global Novel Cholesterol-Lowering Drugs, Market Share of Products (%), 2016 Figure 8.2. Global Novel Cholesterol-Lowering Drugs Market by Product ($million) 2017-2027 Figure 8.3. Global Juxtapid Market Forecast, ($m) 2017-2027 Figure 8.4. Global Kynamro Market Forecast, ($m) 2017-2027 Figure 8.5. Global MK-089 Market Forecast, ($m) 2017-2027 Figure 8.6. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m) 2017-2027 Figure 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($million) 2017-2027 Figure 9.2. Global Cholesterol-Lowering Drugs Market by Geography, Market Share (%), 2016 Figure 9.3. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($million) 2017-2027 Figure 9.4. North America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016 Figure 9.5. USA Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.6. The Average Blood Concentration of LDL-C and TC:HDL-C Ratio, Canada, 2012 to 2013 Figure 9.7. Canada Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.8. Mexico Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.9 South America Cholesterol-Lowering Drugs Market Forecast, by Country ($million) 2017-2027 Figure 9.10. South America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016 Figure 9.11. Brazil Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.12. Argentina Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.13. Paraguay Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.14. Bolivia Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.15. Rest of South America Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.16. Europe Cholesterol-Lowering Drugs Market Forecast by Country($million) 2017-2027 Figure 9.17. Europe Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016 Figure 9.18. France Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.19. Germany Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.20. UK Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.21. Spain Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.22. Italy Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.23. Rest of Europe Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027 Figure 9.24. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($million) 2017-2027 Figure 9.25. Asia-Pacific Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016 Figure 9.26. China Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.27. Japan Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.28. India Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.29. Australia Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.30. Thailand Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.31. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.32. RoW Cholesterol-Lowering Drug Market Forecast by Country,($million) 2017-2027 Figure 9.33. Rest of World Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016 Figure 9.34. Middle East Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.35. Africa Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 9.36. Other Countries Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027 Figure 10.1. Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2017-2027 Figure 11.1. AstraZeneca Plc, Revenue, ($million), 2012-2016 Figure 11.2. AstraZeneca Plc, Geographical Presence Share (%), 2016 Figure 11.3. Merck & Co. Inc., Revenue, ($million), 2012-2016 Figure 11.4. Merck & Co. Inc., Product Segments Share (%), 2016 Figure 11.5. Merck & Co. Inc., Geographical Presence Share (%), 2016 Figure 11.6. Pfizer Inc., Revenue, ($million), 2012-2016 Figure 11.7. Pfizer Inc., Product Segments Share (%), 2016 Figure 11.8 Pfizer Inc., Geographical Presence Share (%), 2016 Figure 11.9. Daiichi Sankyo Co., Ltd., Revenue, ($million), 2012-2016 Figure 11.10. Daiichi Sankyo Co., Ltd., Product Segments Share (%), 2016 Figure 11.11. Daiichi Sankyo Co., Ltd., Geographical Presence Share (%), 2016 Figure 11.12. AbbVie Inc., Revenue, ($million), 2012-2016 Figure 11.13. AbbVie Inc., Product Segments Share (%), 2016 Figure 11.14. AbbVie Inc., Geographical Presence Share (%), 2016 Figure 11.15. Novartis AG, Revenue, ($million), 2012-2016 Figure 11.16. Novartis AG, Product Segments Share (%), 2016 Figure 11.17. Novartis AG, Geographical Presence Share (%), 2016 Figure 11.18. Sanofi S.A., Revenue, ($million), 2012-2016 Figure 11.19. Sanofi S.A., Product Segments Share (%), 2016 Figure 11.20. Sanofi S.A., Geographical Presence Share (%), 2016 Figure 11.21. Amgen Inc., Revenue, ($million), 2012-2016 Figure 11.22. Amgen Inc., Product Segments Share (%), 2016 Figure 11.23. Amgen Inc., Geographical Presence Share (%), 2016 Figure 11.24. Bristol-Myers Squibb, Revenue, ($million), 2012-2016 Figure 11.25. Bristol-Myers Squibb, Product Segments Share (%), 2016 Figure 11.26. Bristol-Myers Squibb, Geographical Presence Share (%), 2016 Figure 12.1. World Cholesterol-Lowering Drug Market by Region: Revenues ($m), 2017-2027 Figure 12.2. World Cholesterol-Lowering Drugs Market Forecastb by Segment: Revenue ($m), 2017-2027 Figure 12.3. World Cholesterol-Lowering Drugs Market Driving Factors
List of Organizations Mentioned in the Report American College of Cardiology American Heart Association Department of Pharmaceuticals (India) European Society of Cardiology National Health Service National Heart, Lung, and Blood Institute United Nations Department of Economic and Social Affairs US Dietary Guidelines Advisory Committee US Food and Drug Administration World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Global Cholesterol-Lowering Drugs Market 2017-2027
Download sample pages
Complete the form below to download your free sample pages for Global Cholesterol-Lowering Drugs Market 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
